9903588-3
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		(11) International Publication Number:
A61K 31/18, 31/63, 47/06, 47/10, 47/32, 9/06, 47/00	A1	WO 98/37879
		(43) International Publication Date: 3 September 1998 (03.09.98)

(21) International Application Number: PCT/EP98/00990

(22) International Filing Date: 20 February 1998 (20.02.98)

(30) Priority Data:
MI97A000408 25 February 1997 (25.02.97) IT

(71) Applicant *(for all designated States except US)*: HELSINN HEALTHCARE S.A. [CH/CH]; Via Pian Scairolo, CH–6912 Pazzallo–Lugano (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BADER, Stefano [IT/IT]; Via Ponte Vetero, 1, I–20121 Milano (IT). HÄUSERMANN, Enrique [CH/IT]; Via Ponte Vetero, 1, I–20121 Milano (IT). MONTI, Tiziana [IT/CH]; Via Pian Scairolo, CH–6912 Pazzallo–Lugano (CH).

(74) Agent: MINOJA, Fabrizio; Bianchetti, Bracco, Minoja S.r.l., Via Rossini, 8, I–20122 Milano (IT).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NIMESULIDE GEL SYSTEMS FOR TOPICAL USE

(57) Abstract

The present invention relates to nimesulide topical formulations comprising a carboxyvinylpolymer neutralized as a gel–forming agent or a polyacrylamide–isoparaffin and a solvent selected from the group consisting of ethanol, isopropanol and diethylene glycol monoethyl ether, and to the process for the preparation thereof. Said formulations have advantages such as higher stability of the system and bioavailability of the active ingredient.